|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer显示文摘Despite recent improvements to current therapies and the emergence of novel agents to manage advanced non-small cell lung cancer(NSCLC),the patients′overall survival remains poor.Re-challenging with first-line chemotherapy upon relapse is common in the management of small cell lung cancer but is not well reported for advanced NSCLC.NSCLC relapse has been attributed to acquired drug resistance,but the repopulation of sensitive clones may also play a role,in which case re-challenge may be appropriate.Here,we report the results of re-challenge with gemcitabine plus carboplatin in 22 patients from a single institution who had previously received gemcitabine plus platinum in the first-line setting and had either partial response or a progression-free interval of longer than 6 months.In this retrospective study,the charts of patients who underwent second-line chemotherapy for NSCLC in our cancer center between January 2005 and April 2010 were reviewed.All the patients who received a combination of gemcitabine and carboplatin for re-challenge were included in the study.These patients were offered second-line treatment on confirmation of clear radiological disease progression.The overall response rate was 15%and disease control rate was 75%.The median survival time was 10.4 months,with 46%of patients alive at 1 year.These results suggest that re-challenge chemotherapy should be considered in selected patients with radiological partial response or a progression-free survival of longer than 6 months to the initial therapy. | Khurum Khan Gerard G Hanna Lynn Campbell Paula Scullin Adnan Hussain Ruth L Eakin Jonathan McAleese | 2013 | Chinese Journal of Cancer2013，32，10： | 3 |
| 2 | Personalising pancreas cancer treatment:When tissue is the issue显示文摘The treatment of advanced pancreatic cancer has not moved much beyond single agent gemcitabine until recently when protocols such as FOLFIRINOX(fluorouracil,leucovorin,irinotecan and oxaliplatin)and nab-paclitaxelgemcitabine have demonstrated some improved outcomes.Advances in technology especially in massively parallel genome sequencing has progressed our understanding of the biology of pancreatic cancer especially the candidate signalling pathways that are involved in tumourogenesis and disease course.This has allowed identification of potentially actionable mutations that may be targeted by new biological agents.The heterogeneity of pancreatic cancer makes tumour tissue collection important with the aim of being able to personalise therapies for the individual as opposed to a one size fits all approach to treatment of the condition.This paper reviews the developments in this area of translational research and the ongoing clinical studies that will attempt to move this into the everyday oncology practice. | Katrin M Sjoquist Venessa T Chin Lorraine A Chantrill Chelsie O'Connor Chris Hemmings David K Chang Angela Chou Marina Pajic Amber L Johns Adnan M Nagrial Andrew V Biankin Desmond Yip | 2014 | World Journal of Gastroenterology2014，20，24： | 2 |
| 3 | Acute ischemie stroke and infections显示文摘 | CATALINA C I ADNAN H S ELAD I L | 2011 | J Stroke and Ccrcbrovascular Diseases2011，20，1： | 1 |
| 4 | Regorafenib (BAY 73-4506):a new oral multikinase inhibitor of angiogenic,stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity显示文摘 | Wilhelm S M Dumas J Adnane L | | 0，，01： | 1 |
| 5 | A distributed industrial battery manage- ment network 显示文摘 | DARREN L ADNAN A | 2004 | IEEE Transactions on Industrial Electronics2004，51，6： | 1 |
| 6 | A distributed industrial battery manage-ment network 显示文摘 | DARREN L ADNAN A | 2004 | IEEE Transactions on Industrial HIcctronics2004，51，6： | 1 |
| 7 | Preclinical overview of sorafenib,a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling显示文摘 | Wilhelm SM Adnane L Newell P | | 0，，10： | 1 |
| 8 | Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling 显示文摘 | Wilhelm SM Adnane L Newell P | 2008 | Mol Cancer Ther2008，7，： | 1 |
| 9 | Preclinical overview of sorafenib,a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling显示文摘 | Wilhelm SM Adnane L Newell P | 2008 | Mol Cancer Ther2008，7，10： | 1 |
| 10 | Effects of transplantation of olfactoryensheathing cells in chronic spinal cord injury : a systematic reviewand meta-analysis显示文摘 | Li L Adnan H Xu B | 2015 | Eur Spine J2015，24，5： | 1 |
| 11 | Sorafenib(BAY 43-9006,Nexavar),a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature显示文摘 | Adnane L Trail PA Taylor I | 2006 | Methods Enzymol2006，407，： | 1 |
| 12 | Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature显示文摘 | Adnane L Trail P A Taylor I | 2006 | Methods Enzymol2006，407，： | 1 |
| 13 | Antioxidant activity of different extract of red Pitaya (Hylocereus polyrhizus) seed显示文摘 | ADNAN L OSMAN A HAMID A A | 2011 | International Journal of Food Properties2011，14，6： | 1 |
| 14 | Sorafenib ( BAY 43 - 9006, Nexavar), a dual -action inhibitor that targets RAF/MEK/ ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature显示文摘 | ADNANE L TRAIL P A TAYLOR I | 2006 | Methods Enzymol2006，407，： | 1 |
| 15 | Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity 显示文摘 | Wilhelm S M Dumas J Adnane L | 2011 | Int J Cancer2011，129，1： | 1 |
| 16 | Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling显示文摘 | Wilhelm S M Adnane L Newell P Villanueva A Llovet J M Lynch M | 2008 | Mol Cancer Ther2008，7，： | 1 |
| 17 | Regorafenib (BAY 73-4506) : a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potentpreclinical antitumor activity 显示文摘 | Wilhelm SM Dumas J Adnane L | 2011 | Int J Cancer2011，129，1： | 1 |
| 18 | Preclinical overview of sorafenib, a multikinase inhibi- tor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling 显示文摘 | WILHELM S M ADNANE L NEWELL P et aI | 2008 | Mol Cancer Ther2008，7，10： | 1 |
| 19 | Sorafenib (BAY 43-9006,Nexavar),a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature显示文摘 | Adnane L Trail PA Taylor I | | 0，，： | 1 |
| 20 | Effect of feedingrate and water temperature on growth of juvenile white stur-geon (Acipenser transmontanus)显示文摘 | Silas S O H Paul B L Adnan A S | 1993 | Aquaculture1993，115，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员